Intellipharmaceutics Abuse-Deterrent Oxycodone Program Advances To Next Level
Intellipharmaceutics said that the successful manufacture of clinical batches is required to make the drug eligible for Phase I studies and to establish a clinical program in cooperation
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.